Saxenda for weight loss: what day-one TikTok posts get wrong
Quick answer
The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males. Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist with regulatory approval for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Phase 3 trial data supports average weight loss of 8 to 9% of body weight over 56 weeks, with significant individual variation in response.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @jonnosunshine actually say?
Not much, honestly, and that's fine. This is a day-one check-in. He says he's starting "sixth tender" (almost certainly a speech-to-text mangle of Saxenda), weighs 115 kilos, wears 38-inch trousers, and has a waist measurement of 116 centimeters. That's it. No dosing claims, no miracle promises, just a starting-line selfie in video form.
The baseline metrics he gives are actually useful data points. A waist circumference of 116 cm in a male sits well above the 102 cm threshold that clinical guidelines use to flag substantially elevated cardiometabolic risk. He's not just sharing his weight journey for content; whether he knows it or not, he's documenting a genuinely high-risk metabolic starting point.
Does the science back this up?
He didn't really make scientific claims, so there's nothing to fact-check against the literature here. But starting Saxenda (liraglutide 3.0 mg) at a BMI that almost certainly clears the prescribing threshold is clinically appropriate, and the evidence base for liraglutide at this weight range is real.
The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) found liraglutide 3.0 mg produced an average 8.4 kg greater weight loss than placebo over 56 weeks in non-diabetic adults with obesity. That's meaningful but not dramatic. Importantly, around 63% of participants lost at least 5% of body weight, meaning a meaningful minority don't respond strongly. For someone at 115 kg, 5% is about 5.75 kg. Realistic, not transformative on its own.
What did they get wrong (or right)?
He didn't get anything factually wrong, because he barely made any factual claims. Credit where it's due: not over-promising on day one is actually better than most GLP-1 content on TikTok, where creators routinely inflate expected outcomes or treat these medications as effortless fixes.
The one thing worth flagging is the speech-to-text rendering of "sixth tender" for Saxenda. It sounds trivial, but misspelled or misheard drug names in viral content do contribute to confusion, especially when people search those terms. Saxenda is liraglutide; it is a different molecule from semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). They work on overlapping but distinct receptor pathways, and they are not interchangeable. His content doesn't claim otherwise, but it's worth stating plainly for anyone landing here from a search.
What should you actually know?
Waist circumference matters more than most people realise. The 116 cm measurement he mentions is above the threshold where visceral adiposity independently predicts cardiovascular and metabolic disease risk, separate from total body weight. Lean mass, where fat sits, and how metabolically active that fat is all matter. Waist-to-height ratio is increasingly favoured over BMI alone in research settings (Ashwell et al., 2012, Nutrition Research Reviews).
Saxenda requires dose titration over several weeks, starting at 0.6 mg and working toward 3.0 mg. Side effects, primarily nausea and gastrointestinal discomfort, are common in early weeks and are the main reason people discontinue. The SCALE trial recorded GI adverse events in around 40% of the liraglutide group. Anyone watching this and considering starting should know that week one rarely looks like the results reels they've seen elsewhere.
- Liraglutide is injected once daily, unlike weekly semaglutide
- It works by mimicking GLP-1, a gut hormone that slows gastric emptying and reduces appetite signalling
- It is not a cure for obesity and does not work the same way in everyone
The bottom line
This video is a nothing-burger in terms of medical claims, which is actually a compliment in the GLP-1 content space. He's documenting a real starting point with real numbers. The metrics he shares reflect a genuine cardiometabolic risk profile, and Saxenda is a regulated, evidence-supported medication for his stated situation. Follow the journey with realistic expectations: 5 to 10% body weight loss over 6 to 12 months is the realistic range, not the transformation content that tends to dominate this hashtag.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda for weight loss: what day-one TikTok posts get wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Saxenda for weight loss: what day-one TikTok posts get wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males.
FormBlends verdict
The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males. Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist with regulatory approval for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Phase 3 trial data supports average weight loss of 8 to 9% of body weight over 56 weeks, with significant individual variation in response.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator reports a starting weight of 115 kg and waist circumference of 116 cm, both of which exceed clinical thresholds for obesity-related cardiometabolic risk in adult males. Saxenda (liraglutide 3.0 mg) is a once-daily injectable GLP-1 receptor agonist with regulatory approval for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related comorbidity. Phase 3 trial data supports average weight loss of 8 to 9% of body weight over 56 weeks, with significant individual variation in response.
- Saxenda (liraglutide 3.0 mg) produced mean weight loss of 8.4 kg more than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), roughly 8% of starting body weight.
- A waist circumference above 102 cm in males is a WHO-recognised threshold for substantially increased cardiometabolic risk, separate from BMI alone.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Saxenda (liraglutide 3.0 mg) produced mean weight loss of 8.4 kg more than placebo over 56 weeks in the SCALE trial (Pi-Sunyer et al., 2015, NEJM), roughly 8% of starting body weight.
- A waist circumference above 102 cm in males is a WHO-recognised threshold for substantially increased cardiometabolic risk, separate from BMI alone.
- Around 40% of liraglutide users in phase 3 trials reported gastrointestinal side effects, particularly nausea, most common during the titration phase.
- Liraglutide is injected once daily and requires gradual dose titration from 0.6 mg to 3.0 mg over four to five weeks.
- Saxenda and semaglutide (Ozempic, Wegovy) are different molecules with different dosing schedules and are not interchangeable, despite both being GLP-1 receptor agonists.
- Roughly 37% of people in the SCALE trial did not achieve even 5% body weight loss on liraglutide, so non-response is a real and common outcome.
- Waist-to-height ratio is increasingly supported over BMI as a single cardiometabolic risk marker in adults (Ashwell et al., 2012, Nutrition Research Reviews).
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Jonno · TikTok creator
54.5K views on this video
beginning my weight loss using Saxenda. #saxenda #weightloss #maleweightloss #dadbod #day1
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Jonno, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.